Novartis has filed a lawsuit against Johnson & Johnson claiming it is using misleading advertising to promote the psoriasis drug Tremfya, which omits critical safety data.…
In response to growing concerns about the safety of generic drugs, which emerged following recent valsartan recalls issued over cancer-causing impurities, federal regulators are defending their oversight and monitoring of generic manufacturers.…
Cancer-causing impurities found in recalled valsartan may have been the result of a process that sought to make more of the hypertension drug at a faster pace.…
Tasigna is a blockbuster cancer drug used to treat chronic myeloid leukemia (CML), which has been linked to serious side effects that can constrict and harden arteries, potentially increasing the risk of heart attack, stroke, amputation and sudden death. …
A leading cancer researcher who failed to reveal deep industry ties and millions in payments has been ousted from a leading cancer center and sparked debate about the need for full financial disclosures in scientific research.…
A Tasigna stroke lawsuit can proceed to trial, but plaintiffs cannot pursue punitive damages, a federal court judge has ruled.…
The FDA has announced that it is joining 22 other countries in recalling many versions of generic Diovan (valsartan), which may contain cancer-causing impurities.…
Nearly half a million packs of Zofran, Entresto, Azithromycin and other drugs by Novartis and Sandoz were recalled because they lacked adequate child-proof packaging.…
Europe and Canada are recalling 2,300 batches of valsartan, a generic version of the hypertension and heart drug Diovan, because they could contain impurities that include a cancer-causing agent.…
The FDA has approved the use of the leukemia drug Tasigna for children, despite recent concerns that it could cause artery hardening and thickening.…
